| 39th week of 2014 patent applcation highlights part 48 |
| Patent application number | Title | Published |
|---|
| 20140287980 | FOAM STABILIZATION AND OILY SOIL REMOVAL WITH ASSOCIATIVE THICKENERS - The invention involves foam stabilization compositions that rely upon anonionic/hydrophobic interaction. According to the invention, an associative thickener is used to provide long range nonionic/hydrophobic interaction with the hydrophobic groups of the surfactants present in the same. The interaction must be of sufficient character so that the components can maintain long range intermolecular networking, causing longer lasting and increased foam production, even in the presence of hydrophobic/oily soils. The system provides an environmentally friendly alternative for traditional foaming enhancers such as cocamide DEA. | 2014-09-25 |
| 20140287981 | FOAM STABILIZATION WITH POLYETHYLENEIMINE ETHOXYLATES - The invention involves foam stabilization compositions that rely upon an electrostatic charge interaction. According to the invention, the positively charged class of polymers such as polyethyleneimine (PEI) polymers are used to provide a long range electrostatic interaction with detersive anionic or amphoteric surfactants present in the same. The interaction must be of sufficient character so that the components do not precipitate out, instead causing longer lasting and increased foam production. The system provides an environmentally friendly alternative for traditional foaming enhancers such as cocamide DEA. | 2014-09-25 |
| 20140287982 | PERFUMING COMPOSITIONS AND USES THEREOF - The present invention relates to the field of perfumery. More particularly, it provides a perfuming composition capable of prolonging the release of a perfuming component into the surrounding environment when applied on a body surface. The composition comprises PPG-3 myristyl ether as a fragrance evaporation modulator in the presence of high amounts of ethanol. The invention also relates to consumer articles containing such compositions. It finally provides methods for the perfuming of a body surface and a method for increasing the long-lastingness of a perfuming component using these compositions. | 2014-09-25 |
| 20140287983 | ANTISENSE COMPOSITIONS AND METHODS FOR MODULATING CONTACT HYPERSENSITIVITY OR CONTACT DERMATITIS - Provided are methods and compositions, including topical compositions, for inducing tolerance to a sensitizing agent known to provoke contact hypersensitivity in a subject. Included are methods of topically applying to the subject an effective amount of an antisense composition targeting the start site or splice site of a CFLAR mRNA. | 2014-09-25 |
| 20140287984 | POLYETHYLENE GLYCOL BASED PRODRUG OF ADRENOMEDULLIN AND USE THEREOF - The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders. | 2014-09-25 |
| 20140287985 | NOVEL USES OF ELAFIN - The invention relates to novel uses of the polypeptide elafin, and/or homologues, derivatives or fragments thereof having inhibitory activity against leukocyte elastase for the prevention and treatment of medical conditions like SIRS. | 2014-09-25 |
| 20140287986 | TEMPLATE-FIXED PEPTIDOMIMETICS AS INHIBITORS OF FPR1 - Novel template-fixed β-hairpin peptidomimetics of the general formula (I): cyclo[P | 2014-09-25 |
| 20140287987 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES - The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function. | 2014-09-25 |
| 20140287988 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS - Provided herein are compositions, which include an active pharmaceutical ingredient and macrogol 15 hydroxystearate, and methods for using the same for treating diseases or disorder. | 2014-09-25 |
| 20140287989 | Compounds Binding to the Bacterial Beta Ring - The present invention relates to compounds which bind to the hydrophobic pocket of the β clamp, i.e., to the surface of the β ring with which said protein interacts with other proteins of the bacterial replication complex during DNA replication. These compounds are derived from the acetylated peptide AcQLDLF (P6) to improve their affinity to their target. | 2014-09-25 |
| 20140287990 | COMPOSITIONS AND METHODS TO CONCURRENTLY TREAT AND/OR PREVENT MULTIPLE DISEASES WITH CUPREDOXINS - The present invention relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to treat and/or prevent two or more conditions in a mammalian cell. The invention also relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to concurrently treat and/or prevent two or more conditions in a patient such as HIV, cancer, malaria and inappropriate angiogenesis. | 2014-09-25 |
| 20140287991 | Hepatitis B Virus-Binding Polypeptides and Methods of Use Thereof - The present invention provides non-naturally occurring polypeptides that specifically bind hepatitis B virus (HBV) DNA; and polynucleotides encoding the polypeptides. The present invention further provides methods of detecting HBV DNA; methods of detecting a covalently closed circular DNA (cccDNA) form of HBV; and methods for treating HBV infection. | 2014-09-25 |
| 20140287992 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 2014-09-25 |
| 20140287993 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES - The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 2014-09-25 |
| 20140287994 | PEPTIDES HAVING REDUCED TOXICITY THAT STIMULATE CHOLESTEROL EFFLUX - The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia and inflammation. | 2014-09-25 |
| 20140287995 | STABLE PHARMACEUTICAL FORMULATIONS OF GROWTH FACTOR PEPTIDES - The present disclosure provides pharmaceutical formulations including a kidney growth factor peptide and one or more excipients, wherein the formulations have a pH of greater than about 6.8. The disclosure also provides processes for preparing the formulation and products prepared by such processes. | 2014-09-25 |
| 20140287996 | NEUROPROTECTION BY HEPATIC CELLS AND HEPATOCYTE SECRETORY FACTORS - The present invention relates to compositions and methods for neuroprotection. In particular, provided herein are compositions (e.g., hepatocyte secretory factors) for alleviating and/or protecting against neuronal damage (e.g., resulting from stroke), and methods of use thereof. | 2014-09-25 |
| 20140287997 | USE OF GROWTH HORMONE OR GROWTH HORMONE RECEPTOR AGONISTS TO PREVENT OR TREAT STRESS-SENSITIVE PSYCHIATRIC ILLNESS - The invention relates to methods for treating stress sensitive condition, particularly depression. For instance a subject having or at risk of having a stress-sensitive condition such as depression may be treated with a growth hormone (GH) or an agonist thereof in an effective amount to treat depression. | 2014-09-25 |
| 20140287998 | GLUCAGON FORMULATIONS - Glucagon is formulated in hydrochloric acid buffered, mannitol containing formulations that can be readily lyophilized and rapidly reconstituted for use in dual chamber cartridges and auto-injector device technology. | 2014-09-25 |
| 20140287999 | Use of Natriuretic Peptide for Treating Heart Failure - The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours. | 2014-09-25 |
| 20140288000 | DUAL REACTIVITY POTENT KUNITZ INHIBITOR OF FIBRINOLYSIS - Compositions and methods are disclosed that relate to novel plasmin-inhibiting polypeptides that are structural variants of a human TFPI-2 Kunitz-type proteinase first inhibitor domain (KD1). The polypeptides are potent plasmin inhibitors and in certain embodiments have anti-fibrinolytic activity and/or decreased anti-coagulation activity relative to wild-type TFPI-2 KD1 and are not highly immunogenic. The plasmin-inhibiting polypeptides will find uses as anti-cancer agents, as antifibrinolytic agents, as protease inhibitors, and in other contexts. | 2014-09-25 |
| 20140288001 | KALLIKREIN INHIBITORS AND ANTI-THROMBOLYTIC AGENTS AND USES THEREOF - Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass. | 2014-09-25 |
| 20140288002 | EXTRACELLULAR MATRIX-BINDING SYNTHETIC PEPTIDOGLYCANS - This disclosure provides extracellular matrix-binding synthetic peptidoglycans comprised of one or more synthetic peptides conjugated to a glycan and methods of their use. | 2014-09-25 |
| 20140288003 | INHIBITION OF COLLAGEN SYNTHESIS - Therapies and compositions for reducing collagen synthesis in mammalian cells and tissues wherein the targets are scleraxis, scleraxis-binding sites, receptor-regulated Smads, and/or binding sites for receptor-regulated Smads whereby synergistic interactions between scleraxis proteins and receptor-regulated Smads are reduced, inhibited, interfered with, stopped, and/or prevented thereby reducing, inhibiting and/or interfering with the activation of collagen 1α2 promoter thereby inhibiting collagen production in mammalian cells and tissues. Alternatively, the therapies and compositions may reduce, inhibit, interfere with, stop, and/or prevent binding of the collagen 1α2 promoter to DNA thereby inhibiting expression of the collagen 1α2 gene in mammalian cells and tissues. | 2014-09-25 |
| 20140288004 | LACTOFERRIN AND THE WHITE MATTER - The present invention generally relates to white matter. In particular, the present invention relates to a composition that can be used for promotion the development and/or void loss of white matter. One embodiment of the present invention relates to a composition comprising lactoferrin for use in the promotion of the development of the white matter, in the treatment or prevention of a delayed development of the white matter, and or in the treatment of prevention of a loss of white matter. | 2014-09-25 |
| 20140288005 | COMPOUND FOR TREATMENT OF ALZHEIMER'S DISEASE AND FAMILIAL DEMENTIA - An isolated protein is provided for use in treatment of a condition selected from the group consisting of Alzheimer's disease, familial Danish dementia and familial British dementia in a mammal, including man. The isolated protein is selected from the group consisting of proteins comprising an amino acid sequence having at least 70% identity to residues 90-236 of Bri2 from human; and proteins comprising an amino acid sequence having at least 70% identity to any one of the Brichos domains of Bri2 from human, chimpanzee, bovine, pig, mouse and rat. | 2014-09-25 |
| 20140288006 | PTD-SMAD7 THERAPEUTICS - The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins. | 2014-09-25 |
| 20140288007 | GINGIPAIN INHIBITORY PROPEPTIDES - The disclosure relates to compounds, peptides or peptidomimetics that inhibit, reduce or prevent protease activity and the use of these compounds, peptides or peptidomimetics to treat or prevent a condition. In particular the condition may be periodontal disease. The protease activity may be activity of a gingipain. The compounds, peptides or peptidomimetics of the invention may also be used in assays for the identification of protease inhibitors. | 2014-09-25 |
| 20140288008 | NOVEL BINDING PROTEINS FOR PCSK9 - The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules. | 2014-09-25 |
| 20140288009 | Collagen-like Silk Genes - The present invention relates to silk proteins which can be used to produce silk with a collagen-like structure, as well as nucleic acids encoding such proteins. The present invention also relates to recombinant cells and/or organisms which synthesize silk proteins. Silk proteins of the invention can be used for a variety of purposes such as in the production of personal care products, plastics, textiles, and biomedical products. | 2014-09-25 |
| 20140288010 | Compositions and Methods for Increasing Stem Cell Survival - Compositions and methods of increasing autophagy in a cell, or population of cells are disclosed. The methods generally include contacting the cell or cells with an effective amount of an agent that increases the bioavailability of an active isoform of SDF-1. Exemplary agents include active SDF-1 polypeptides, metformin, and DPP4 inhibitors. The methods can include administering the agent to a subject, or treating cells in vivo, in vitro or ex vivo. In some embodiments, cells are treated ex vivo and then transplanted into a subject. In a preferred embodiment, the cells are mesenchymal stem cells such as those found in bone marrow. The compositions and methods can be utilized in a number of therapeutic applications including increasing the longevity or survival of a graft or transplant, increasing the rate of recovery from an injury, reducing one or more symptoms of a chronic inflammatory disease and reducing effect associated with aging. | 2014-09-25 |
| 20140288011 | GENETIC ASSOCIATION - This invention is directed in part to methods, assays and/or kits for identifying an individual who has an autoimmune disease (such as rheumatoid arthritis), or who has an altered risk for having or developing the autoimmune disease. The methods in one aspect comprise determining the presence or absence of a nucleic acid variant within the somatostatin receptor type 2 (sstr2) gene in the individual's nucleic acids, wherein the presence of the nucleic acid variant is correlated with having the autoimmune disease or the altered risk. The nucleic acid variant may, for example, be a single nucleotide polymorphism (SNP). | 2014-09-25 |
| 20140288012 | METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONS - The disclosure relates to methods for treating a subject suffering from a burn injury or associated complications by administering to the subject an effective amount of an aromatic-cationic peptide. For example, a burn injury may be associated with distant pathophysiological effects, such as hypermetabolism, skeletal muscle dysfunction, and organ damage. The disclosure also relates to methods for protecting a subject from a burn injury by administering an effective amount of an aromatic-cationic peptide to a subject at risk of a burn injury. | 2014-09-25 |
| 20140288013 | METHODS AND COMPOSITIONS FOR THE MANAGEMENT OF CANCER USING 2-DG AND AN IGF-IR INHIBITOR - The disclosure relates to methods and compositions for the management of cancer. In certain embodiments, the disclosure relates to methods of treating or preventing cancer by administering an IGF-IR inhibitor and 2-deoxyglucose to a subject in need thereof. | 2014-09-25 |
| 20140288014 | COMPOSITIONS OF CRUDE ALGAL OIL - The present invention provides compositions for a crude algal oil and methods of making thereof. The compositions can be used to produce a highly pure omega-3 eicosapentaenoic acid (EPA) formulation. | 2014-09-25 |
| 20140288015 | METHODS AND DEVICES FOR AFFECTING NERVE FUNCTION - Various methods and devices are described for affecting nerve function in the carotid body, renal nerves, and other nerves. Syringes, endovascular catheters, drug-eluting balloons, drug-eluting stents, and agent delivery patches are used to deliver a neuromodulatory agent to one or more nerves in order to treat a disease state. | 2014-09-25 |
| 20140288016 | METHOD OF PROVIDING AN ANTI-ULCER TREATMENT WITH EXTRACTS AND ISOLATED FLAVONOIDS FROM EUPHORBIA CUNEATA - The present invention relates to methods of isolating flavonoids from | 2014-09-25 |
| 20140288017 | CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS - The present invention is directed to novel catechol diether compounds, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV 1 and 2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection. | 2014-09-25 |
| 20140288018 | METHODS FOR PREDICTING THE RESPONSE TO ANTI-CANCER TREATMENT WITH AN AGONIST OF TLR7 OR AN AGONIST OF TLR8 - The present invention relates to methods for predicting the response to treatment with an agonist of TLR7, or an agonist of TLR8 or an anti-cancer agent for treating cancer, in particular non-small cell lung cancer comprising the step of detecting the expression of TLR7 or TLR8 in cancer cells of said patient. | 2014-09-25 |
| 20140288019 | Phosphorylated A2A Receptor Agonists - A phosphorylated A | 2014-09-25 |
| 20140288020 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS - Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: | 2014-09-25 |
| 20140288021 | Composition Comprising Arabinogalactan and Polyphenols From Larch Trees - The present invention includes a composition and method of treatment having arabinogalactan and polyphenols from larch trees for the use in prophylactic treatment of upper respiratory tract infections. The invention also includes treatment using such composition. | 2014-09-25 |
| 20140288022 | CROSS-LINKED POLYMER MATRICES, AND METHODS OF MAKING AND USING SAME - Functionalized chondroitin sulfate, cross-linked polymer matrices comprising functionalized chondroitin sulfate, and methods of making and using the same are provided. Such polymer matrices may be used for tissue engineering, reconstructing cartilage, and the like. Kits are also provided for detection of cartilage degrading enzymes. | 2014-09-25 |
| 20140288023 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 2014-09-25 |
| 20140288024 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - Methods and compositions relating to CDP-epothilone conjugates are described herein. | 2014-09-25 |
| 20140288025 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES - The invention relates to fatty acid antiviral conjugates; compositions comprising an effective amount of a fatty acid antiviral conjugate; and methods for treating or preventing a viral infection comprising the administration of an effective amount of a fatty acid antiviral conjugate. | 2014-09-25 |
| 20140288026 | INSECTICIDAL PAINTS - A one pack aqueous insecticidal architectural coating composition comprising an aqueous dispersion of polymer particles as binder and further comprising, based on the total liquid paint formulation, i) from 0.1 to 4.0 wt % insecticide; ii) from 0.5 to 6.5 wt % dibasic ester solvent wherein the insecticide is located in the polymer particles and the polymer particles are film forming at ambient temperatures. | 2014-09-25 |
| 20140288027 | Derivative of Butylphthalide and Preparation Method and Use Thereof - (−)-(S)-3-(3′-hydroxy)-butylphthalide (a compound shown by Formula I) and an ester formed of the same and an acid are proved by experiments to be applicable to treatment and prevention of cerebral ischemic diseases and have a sleep-improving function. The acid refers to a pharmaceutically acceptable inorganic or organic acid. The inorganic acid refers to nitric acid, sulfuric acid, or phosphoric acid. In addition to an acid radical, the organic acid at least comprises at least one of an amino group, a hydroxyl group, and a carboxyl group. None of the compound shown by Formula I and the ester thereof is water-soluble. An ester generated from the compound and the acid further react with an acid or a base to generate a salt which is water-soluble and is used to prepare injection preparation. The experiment proves that the salt does not stimulate vessels. | 2014-09-25 |
| 20140288028 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR - The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I. | 2014-09-25 |
| 20140288029 | INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE - A method of treating myocardial infarction in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer. | 2014-09-25 |
| 20140288030 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF - This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress. | 2014-09-25 |
| 20140288031 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING - The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens. | 2014-09-25 |
| 20140288032 | AGENTS AND DEVICES FOR USE IN PREVENTION OF RESTENOSIS - Agents that inhibit or prevent restenosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on cell proliferation, thrombosis, tissue modeling, and inflammation. Treatment for restenosis is provided using compositions of the invention. | 2014-09-25 |
| 20140288033 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND - The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder. | 2014-09-25 |
| 20140288034 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF - A compound having an ability to bind to an S1P receptor and represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like: | 2014-09-25 |
| 20140288035 | 18-METHYL-6,7-METHYLENE-3-OXO-17-PREGN-4-ENE-21,17B-CARBOLACTONES, PHARMACEUTICAL PREPARATIONS COMPRISING SAID COMPOUNDS AND USE THEREOF IN THE TREATMENT OF ENDOMETRIOSIS - The present invention relates to 18-methyl-6,7-methylene-17-pregn-4-ene-21,17β-carbolactones of general formula I | 2014-09-25 |
| 20140288036 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY - Described are steroidal C-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods for their synthesis are also described, which include methods having a step of nucleophilic vinylic “addition-elimination” substitution reaction of 3β-acetoxy-17-chloro-16-formylandrosta-5,16-diene or analogs thereof and benzoazole or pyrimidinoazole nucleophiles and methods having a palladium catalyzed cross-coupling reaction of 17-iodoandrosta-5,16-dien-3β-ol or analogs thereof with tributylstannyl diazines. The compounds are potent inhibitors of human CYP17 enzyme as well as potent antagonists of both wild type and mutant androgen receptors (AR). The compounds are useful for the treatment of human prostate cancer. | 2014-09-25 |
| 20140288037 | NOVEL COMPOSITIONS AND METHODS FOR TREATING PROSTATE CANCER - Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions. In some embodiments, the solid matrix comprises a polymer. In some embodiments, the polymer is soluble in an aqueous solution. In particular embodiments, the aqueous solution is water. In other embodiments, the aqueous solution has a pH of 5.0 or greater. | 2014-09-25 |
| 20140288038 | DEVICE FOR TRANSDERMAL ADMINISTRATION OF DRUGS INCLUDING ACRYLIC POLYMERS - A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent. | 2014-09-25 |
| 20140288039 | LIPOBALANCED LONG CHAIN TESTOSTERONE PRODRUGS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select lipobalanced testosterone prodrugs and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a lipobalanced testosterone prodrugs and a pharmaceutically acceptable carrier. | 2014-09-25 |
| 20140288040 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION - The invention provides compounds of the formula (6): | 2014-09-25 |
| 20140288041 | Aryl- or Heteroaryl-Substituted Benzene Compounds - The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes. | 2014-09-25 |
| 20140288042 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds of Formula I having the following general structure: | 2014-09-25 |
| 20140288043 | PYRAZOLOPYRIDINE COMPOUNDS - A first aspect of the invention relates to a compound of formula (1A) or (1B), or a pharmaceutically acceptable salt thereof, | 2014-09-25 |
| 20140288044 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS - The invention relates to compounds, pharmaceutical compositions and medicaments comprising such compounds, and the use of these compounds, compositions, and medicaments in methods of treating diseases and disorders. | 2014-09-25 |
| 20140288045 | COVALENT INHIBITORS OF KRAS G12C - Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein. | 2014-09-25 |
| 20140288046 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES - The invention relates to a compound of formula (I) | 2014-09-25 |
| 20140288047 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z | 2014-09-25 |
| 20140288048 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. | 2014-09-25 |
| 20140288049 | 2-Thiopyrimidinones - Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions. | 2014-09-25 |
| 20140288051 | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS - New bicyclic compounds, their preparation, and their use as antibacterial agents, either alone or in combination with an antibiotic for the treatment of infections caused by β-lactamase-producing pathogenic bacteria, are described. | 2014-09-25 |
| 20140288052 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS - Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. | 2014-09-25 |
| 20140288053 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES - The invention relates to new pyridopyrazine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. | 2014-09-25 |
| 20140288054 | GENETIC MARKERS OF MENTAL ILLNESS - This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof. | 2014-09-25 |
| 20140288055 | COMPOSITIONS AND METHODS FOR DIAGNOSIS OF SCHIZOPHRENIA - Provided is a method for diagnosis of schizophrenia, which comprises: detecting G72 gene product in a body fluid sample from a subject by an assay to determine G72 expression level; comparing said G72 expression level to a baseline G72 expression; and relating the G72 expression level to the patient's risk of schizophrenia by assigning an increased risk of schizophrenia when said G72 expression level is greater than said baseline G72 expression. Through detecting G72 expression level in a peripheral sample, the method can be simply performed by an in vitro assay and accurately predict or diagnose a subject with schizophrenia. | 2014-09-25 |
| 20140288056 | METHODS FOR NON-TOXIC TREATMENT FOR DRUG WITHDRAWAL - The disclosure provides a method to administer noribogaine to a human patient having drug addiction in dosages that provide efficacy without leading to any significant deleterious clinical signs. | 2014-09-25 |
| 20140288057 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA - There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetylcholinesterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetylcholinesterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetylcholinesterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HT | 2014-09-25 |
| 20140288058 | METHODS OF PREPARING PHARMACEUTICAL COMPOSITIONS COMPRISING ESLICARBAZEPINE ACETATE AND METHODS OF USE - The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate. | 2014-09-25 |
| 20140288059 | THERAPEUTIC COMPOSITIONS AND METHODS - PAD4 inhibitory compositions and methods for their use in treatment of cancer and autoimmune disease are provided according to embodiments of the present invention. | 2014-09-25 |
| 20140288060 | Selective inhibition of MALT1 protease by phenothiazine derivatives - The invention relates to a compound for use in treating a cancer, wherein the cancer depends on the proteolytic activity of the MALT1 protease, and wherein the compound has the general formula (I) | 2014-09-25 |
| 20140288061 | INSECTICIDE COMPOSITIONS AND PROCESS - A synergistic insecticide composition comprising: | 2014-09-25 |
| 20140288062 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF - Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes. | 2014-09-25 |
| 20140288063 | Heterocyclic Substituted Pyrimidine Compound - The present invention pertains to the field of medical technology, and particularly relates to a heterocyclic substituted pyrimidine compound represented by General Formula (I) and its pharmaceutically acceptable salt thereof, wherein R | 2014-09-25 |
| 20140288064 | Nitrogen containing heterocyclic compounds - Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed. | 2014-09-25 |
| 20140288065 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS - The present invention provides a pyrrolidine compound of General Formula (1) | 2014-09-25 |
| 20140288066 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS - The invention relates to compounds of formula (I) | 2014-09-25 |
| 20140288067 | CARM1 INHIBITORS AND USES THEREOF - Provided herein are compounds of Formula (I): | 2014-09-25 |
| 20140288068 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH - In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula II, or Formula III. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease and cancer, using a compound of Formula I, Formula II, or Formula III. | 2014-09-25 |
| 20140288069 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS - The present invention relates to amino imidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said 10 compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. | 2014-09-25 |
| 20140288070 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR - Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease. | 2014-09-25 |
| 20140288071 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE - Compounds are disclosed for the treatment, management and prevention of diseases and disorders affecting the bone. Particular compounds are potent inhibitors of Notum Pectinacetylesterase, and are of the formula: | 2014-09-25 |
| 20140288072 | 5 - BENZYLAMINOMETHYL - 6 - AMINOPYRAZOLO [3, 4 -B] PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS - The present application relates to a series of substituted pyra-zolopyridin-6-amines having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. Wherein R, R | 2014-09-25 |
| 20140288073 | Method of Treating Gastrointestinal Stromal Tumors - The present invention relates to a method of treating gastrointestinal stromal tumors (GIST), especially GIST, which is progressing after imatinib therapy or after imatinib and sunitinib therapy, using a combination comprising (a) a c-kit inhibitor and (b) a PI3K inhibitor or FGFR inhibitor. | 2014-09-25 |
| 20140288074 | FUNGICIDAL PYRAZOLES - Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, fungicides: | 2014-09-25 |
| 20140288075 | Isoxazole compound for the treatment of cancer - The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multicentric Castleman disease and/or psioriasis. | 2014-09-25 |
| 20140288076 | HETEROARYL COMPOUNDS AND THEIR USES - The present invention provides a compound of formula (I): | 2014-09-25 |
| 20140288077 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY - In one aspect, the invention relates to substituted 4-phenoxyphenol analogs, derivatives thereof, and related compounds, which are useful as inhibitors of proliferating cell nuclear antigen (PCNA); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating hyperproliferative disorders associated with PCNA using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2014-09-25 |
| 20140288078 | USE OF PHOSPHODIESTERASE INHIBITORS FOR TREATING MULTIDRUG RESISTANCE - The present invention relates to methods of treating multidrug resistance in cancerous cells with phosphodiesterase (PDE) inhibitors, e.g., PDE5 inhibitors. More specifically, the invention relates to methods of treating multidrug resistance that arises, e.g., during administration of chemotherapeutic/antineoplastic (anticancer) agents for treatment of cancer, with a PDE5 inhibitor (e.g., sildenafil, vardenafil, and tadalafil). The invention also relates to methods of treating cancer, e.g., multidrug resistant cancer, using a PDE5 inhibitor in combination with an antineoplastic therapeutic agent. Further, the invention relates to pharmaceutical compositions for treating multidrug resistant cancers comprising a PDE5 inhibitor, or a combination of a PDE5 inhibitor and an antineoplastic agent. | 2014-09-25 |
| 20140288080 | THERAPEUTIC METHODS AND AGENTS FOR TREATING MYOTONIC DYSTROPHY - The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids. | 2014-09-25 |
| 20140288081 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS - Compounds of general formula I: | 2014-09-25 |
